Chronic liver injury triggers liver fibrosis and hepatocellular carcinoma (HCC), the third leading cause of cancer-related mortality. Cyclin E1 (CcnE1, formerly designated Cyclin E) is a regulatory subunit of the Cyclin-dependent kinase 2 (CDK2). It is overexpressed in approximately 70% of human HCCs correlating with poor prognosis, while the relevance of its orthologue Cyclin E2 (CcnE2) loss of CcnE1 resulted in significant reduction of liver tumorigenesis, while deletion of CcnE2 had no effect on HCC formation. CcnE1, but not its orthologue CcnE2, substantially contributes to hepatic inflammatory response, liver disease progression, and hepatocarcinogenesis in NEMO Δhepa mice.
Introduction
Hepatocellular carcinoma (HCC) represents the third leading cause of cancer-related mortality with increasing incidence and poor prognosis [1] . In general, HCC develops as a consequence of chronic hepatitis and continuous cycles of inflammatory cell death and compensatory proliferation, eventually resulting in genomic aberrations and instability of hepatocytes. Pre-malignant hepatocytes typically accumulate oncogenic mutations in cell cycle-related signaling molecules such as c-myc, p53, Rb, and several cyclins [2] . For instance, several independent studies showed that Cyclin E1 (CcnE1, formerly designated Cyclin E) is overexpressed in approximately 65-70% of human HCCs [3, 4] which was associated with poor prognosis.
CcnE1 and its orthologue Cyclin E2 (CcnE2) are the canonical regulatory subunits of Cyclin-dependent kinase 2 (CDK2). Activity of the CcnE/CDK2 kinase complex peaks at G1-/S-phase transition [5] , pointing to an important role of both E-type cyclins and CDK2 in this process. Surprisingly, single genetic inactivation of either CcnE1, CcnE2, or CDK2 in mice does not affect overall development, viability, or organ homeostasis besides sterility in CDK2 and CcnE2 knockout mice [6] [7] [8] , indicating a high functional redundancy of interphase cyclins and CDKs for general cell cycle regulation.
Mice simultaneously lacking CcnE1 and CcnE2 are unable to undergo normal embryonic development and die during embryonic development at day 11.5. However, this is due to a failure of endoreplication in trophoblast giant cells affecting placenta development, but not related to impaired cell cycle progression. Accordingly, CcnE1/E2 double-deficient murine embryonic fibroblasts are able to proliferate, but are incapable to re-enter the cell cycle from starvation-induced quiescence and are also resistant to oncogenic transformation. This suggests that overall CcnE activity is essential for the transition from quiescence to the active cell cycle, whereas CcnE1 and CcnE2 share at least some overlapping functions [6] . Besides its canonical Δhepa livers of 8-week-old mice display upregulation of E-type Cyclins. a CcnE1 and b CcnE2 qRT-PCR of liver mRNA was determined for NEMO f/f (n = 5), CcnE1
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In the liver, we recently identified unique functions of CcnE1 and CcnE2 in liver regeneration and liver fibrosis. Following partial hepatectomy in mice, lack of CcnE1 had only a minor effect on hepatocyte proliferation and liver regeneration, while CcnE2 −/− livers showed enhanced CcnE1 expression, accelerated and sustained DNA synthesis, and hepatomegaly, defining CcnE2 as a negative regulator of CcnE1 [11] . Moreover, we demonstrated that CcnE1 is essential for activation, proliferation, and survival of hepatic stellate cells during liver fibrosis initiation. Accordingly, CcnE1 −/− mice are protected from CCl 4 -mediated liver fibrogenesis, whereas CcnE2 −/− mice displayed even accelerated fibrogenesis [12] . The role of Cyclin E during hepatocarcinogenesis was investigated in a study of Pok et al. [13] , were they used dysplastic hepatocytes and HCCs obtained from Diethylnitrosamine (DEN) treated mice. Their finding shows that Cyclin E is expressed in dysplastic liver and HCCs at the time when wild-type p53 expression and function in livers was disrupted. By performing knockdown experiments in primary HCC cells, they were able to show that Cyclin E was responsible for regulating wild-type p53. Cyclin E knockdown increased p53 and p21, diminished antiapoptotic Bcl-XL, and reduced cell viability. Whereas, blocking p53 enhanced Cyclin E, Bcl-XL expression, and increased proliferation. p53 can induce the expression of microRNA-34 (miR-34) and it is known that ectopic miR-34 expression recapitulates the biological effects of p53 on growth arrest and apoptosis by inhibition of Cyclin E. The study of Pok et. al. suggests that Cyclin E and p53 inversely regulate each other's expression very likely via the intermediary miR-34.
We recently established a novel mouse model of inflammatory hepatocarcinogenesis by deleting the NFkappa-B essential modulator (NEMO) specifically in hepatocytes (NEMO Δhepa ) [14, 15] . NEMO Δhepa mice display a complex phenotype with spontaneous liver apoptosis, compensatory hepatocyte proliferation, steatohepatitis, fibrosis, and HCC as end stage disease, thereby perfectly reflecting chronic liver disease progression in humans [16] . The aim of the present study was to explore the role of CcnE1 and CcnE2 in vivo for chronic liver disease progression and hepatocarcinogenesis. (Fig. 1a, b) .
To assess the impact of E-type cyclins for cell proliferation, we performed Ki67 staining. In all strains, hepatocyte-specific NEMO deletion triggered increased spontaneous cell proliferation in the liver (Fig. 1c) showed the same basal proliferation (Fig. 1c) . Of note, the liver/body weight ratio was identical in all groups including controls at this age ( Fig. 1d ).
Loss of CcnE1 attenuates overall liver injury and inflammation in NEMO Δhepa animals
Liver injury was assessed by measuring alanine aminotransferase (ALT) levels in the serum of the animals. In agreement with our previous reports, ALT activity was substantially elevated in NEMO Δhepa mice (Fig. 2a) , and ablation of CcnE2 in these animals had no effect on overall liver injury. In contrast, constitutive deletion of CcnE1 in NEMO Δhepa mice resulted in approximately 50% reduction of ALT activity hinting at a substantially improved liver injury due to lack of CcnE1. Hepatic inflammation was further analyzed by immunostaining and qRT-PCR quantification of the proinflammatory factors CD45, TNFα, CCR2, and F4/80. These measurements confirmed that ablation of CcnE1 acts anti-inflammatory in NEMO Δhepa livers showing reduced infiltration of CD45-positive and F4/80-positive leukocytes (Fig. 2b, c, Supplementary Figure 1 
Hepatocarcinogenesis is ameliorated in the absence of CcnE1 expression
The previous experiments suggested a unique function of CcnE1 for early inflammatory response, overall liver injury, and cell proliferation in the NEMO Δhepa model. We next (Fig. 4a) , which are typical for the NEMO Δhepa model. In sharp contrast, we did not observe significant changes in tumor formation due to ablation of CcnE2 (Fig. 4a-c) . These findings were confirmed by determining total liver weights ( Fig. 4d ) and liver weight indices (Fig. 4e ) of all experimental animals. Accordingly, absolute and relative weights of NEMO Δhepa /CcnE1
−/− livers were significantly reduced compared to both reference groups supporting the lower tumor load due to lack of CcnE1. A recent study showed that heat shock protein 70 (hsp70) is a molecular marker for early HCC stages [17] . In order to characterize the tumorous liver tissue areas, we thus performed immunostaining for hsp70. In agreement with the previous data, liver tissue (Fig. 6a, compare Fig. 4a ). Further quantitative analysis of tumor initiation (Fig. 6b ) and tumor progression (Fig. 6c) confirmed that deletion of CDK2 in hepatocytes does not affect overall liver tumor formation in NEMO Δhepa mice. In agreement, liver/body weight ratios were not significantly different between both groups (Fig.  6d) . Additionally, no significant differences in serum transaminases were found between NEMO Δhepa /CDK2 Δhepa and NEMO Δhepa mice (Fig. 6e, f) .
We therefore tested CDK2 kinase activity during disease progression in NEMO Δhepa mice. Interestingly, we only detected elevated CDK2 kinase activity in 8-week-old NEMO Δhepa mice representing the early inflammatory phase of disease progression, while CDK2 kinase was at best slightly above background in 52-week-old animals. However, at this later stage comprising advanced liver tumors, we detected enhanced CDK1 kinase activity (Fig. 6g) . Altogether the data suggest that the basal inflammation in NEMO Δhepa mice is associated with CDK2 kinase while in older mice in this model there is less CDK2 but increased CDK1 activation.
Discussion
The understanding of the molecular mechanisms involved in chronic liver diseases and HCC development is crucial, in order to develop novel therapeutic treatment options. CcnE1 is overexpressed in approximately 65-70% of human HCCs 
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, NEMO Δhepa (n = 10), and NEMO Δhepa /CDK2 Δhepa (n = 7). g CDK2 and CDK1 kinase activities were analyzed in livers of NEMO Δhepa mice at the age of 8 and 52 weeks (n = 3). Cre-negative littermates (NEMO f/f ) of matching age were used as controls (n = 3). IP: Immunoprecipitation of native CDK2 or CDK1 kinase complexes. Phosphorylated histone H1 (phistone H1) is highlighted by arrows. Input control: 5% of the supernatant from immunoprecipitations was probed for GAPDH expression to prove equal starting amounts of protein. (Values are mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001.) [3, 4] 
An earlier study with HCC cell lines overexpressing the oncogene CcnE demonstrated that an siRNA approach reduced CcnE overexpression by 90 % [4] . This resulted in enhanced apoptosis of HCC cells and their proliferation was blocked. Additionally, when these cells were injected into nude mice, siRNA treatment also resulted in reduced growth of these cells in vivo [4] . These results demonstrate an essential role of Cyclin E for HCC growth. However, this initial siRNA approach targeted CcnE1 at a site, which has high homology with CcnE2 (data not shown) as CcnE2 was only discovered at this time [18] . Therefore, in their work, the authors could not distinguish between the specific function of either CcnE1 or CcnE2 for the growth of HCC.
Therefore, the aim of the present study was to better define the role of CcnE1 or CcnE2 for the growth of HCC. As a model, we used NEMO Δhepa mice as inactivation of NEMO is frequently found in human HCCs [1] . Hence, the NEMO Δhepa model represents an interesting approach to study human-related mechanisms of chronic liver disease progression in vivo.
Our former studies showed that in 8-week-old NEMO Δhepa livers, a continuous apoptotic response triggers hepatocyte proliferation, which leads to chronic inflammation and consequently disease progression. These mechanisms are associated with an upregulation of different cell cycle regulators [14] [15] [16] . Thus, we first aimed to differentiate between the relevance of both E-type cyclins for disease progression in this model and generated NEMO Δ-hepa /CcnE1 −/− and NEMO Δhepa /CcnE2 −/− animals.
Interestingly these in vivo experiments showed that CcnE1, but not CcnE2, is essential to determine disease progression in this model. The animals had less and smaller HCCs. These results suggest that CcnE1 is involved in tumor initiation and tumor progression in hepatocytes. We conclude that CcnE1 comprises a unique, non-redundant function for malignant hepatocyte transformation and growth, as our earlier results using the model of partial hepatectomy demonstrated that CcnE1 is dispensable for the proliferation of non-malignant hepatocytes after tissue loss [11] .
One important question that was not addressed in the present study is the tissue-specific relevance of Cyclin E1 for tumor growth. Obviously besides hepatocytes, other cells are relevant for HCC progression. However, from the initial experiments targeting Cyclin E via an siRNA approach specifically in HCC cells in vitro and in vivo, it is obvious that Cyclin E in hepatoma cells contributes to the growth of these cells.
CcnE1 and CcnE2 both bind and activate CDK2, which is thought to be an essential step for cell cycle progression. Therefore, we next asked the question, if CDK2 alone might be essential to determine the effect on tumor growth as found in NEMO Δhepa /CcnE1 kinase assay and indeed the results suggest that in the NEMO Δhepa model, hepatocarcinogenesis is not dependent on CDK2 alone but also on CDK1. Therefore, we conclude that CcnE1 has a unique, CDK2-independent oncogenic function in hepatocytes, which cannot be replaced by CcnE2. As CcnE1 is also dispensable for proliferation in healthy, non-transformed hepatocytes, it represents an attractive therapeutic target. Interestingly, a unique function for CcnE1 was recently also discovered in hepatic stellate cells (HSCs), where genetic inactivation of Cyclin E1 prevents activation, proliferation, and survival of HSC and protects from liver fibrogenesis [12] . Therefore, these results suggest that CcnE1 can potentially contribute to tumor growth in different NPCs, e.g., HSCs and immune cells. At present, it is unclear if CcnE1 works in NPCs alone or after binding to CDK2.
Besides the hepatocyte-specific function of CcnE1, our study also indicated that its expression in NPCs may contribute to tumor progression. Our study revealed that the absence of CcnE1 expression in 8-week-old NEMO Δhepa animals had a minor impact on hepatocyte proliferation, but instead had a beneficial impact on liver injury. Furthermore, assessing inflammation in these mice by determining infiltration of CD45-and F4/80-positive leukocytes as well as inflammation markers such as TNFα and CCR2 showed that reduced liver injury in NEMO Δhepa /CcnE1 −/− mice was associated with an amelioration of the inflammatory response. During the last decades, evidences have been obtained showing a link between inflammation and tumorigenesis [19] . The most confirmed tumor-promoting cytokines are "M1 cytokines" such as TNFα [19] . TNFα was shown to promote the growth of HCCs in mice lacking the Pglycoprotein Mdr2, which develop cholestatic inflammation followed by HCC [19, 20] . In the present study, the reduced inflammatory environment was also associated with reduced HCC growth in NEMO Δhepa /CcnE1 −/− , but not in NEMO Δhepa /CcnE2 −/− livers. Therefore, the reduced inflammatory response found in NEMO Δhepa /CcnE1
−/− animals could of course also be a result of the impaired response in hepatocytes. However, as indicated by the divergence between hepatocyte proliferation and inflammation in 8-week-old animals, these results strongly suggest that CcnE1 in NPCs, e.g., HSCs or monocytes, also contribute to reduced HCC growth in CcnE1-deficient NEMO Δhepa livers. For example, it was recently demonstrated that a pre-clinical targeting of Cyclin E1 using stabilized siRNA has a high anti-fibrotic therapeutic potential [21] suggesting that this might also be relevant to prevent the growth of HCCs. In summary, our study demonstrates that CcnE1, but not CcnE2, is essential for the initiation and progression of HCCs. This mechanism in hepatocytes is CcnE1-specific and CDK2-independent. Additionally, our results suggest that CcnE1 in NPCs contributes to the growth of HCC and hence makes CcnE1 an attractive therapeutic target for chronic liver diseases.
Material and methods

Animal experimentation
Mice were treated in accordance with the guidelines of the National Academy of Sciences (NIH publication 86-23 revised 1985) and maintained in the animal facility of the University Hospital RWTH Aachen. Animal studies were approved by the regional authorities for nature, environment, and consumer protection of the state North RhineWestphalia (LANUV, Germany).
Hepatocyte-specific NEMO Δhepa and CDK2 Δhepa knockout mice were generated as recently described [15, 22] . The generation of constitutive CcnE1 −/− and CcnE2 −/− knockout mice has been previously described [6] . Double knockout mice (NEMO Δhepa /CcnE1 −/− , NEMO Δhepa /CcnE2 −/− , and NEMO Δhepa /CDK2 Δhepa mice) were generated by crossing NEMO Δhepa mice with the corresponding single knockout mice. All strains were kept on a C57BL/6 background. Progression of chronic liver disease was examined in 8-, 26-, and 52-week-old animals. Liver weight and body weight were recorded; serum and liver tissue were collected.
qRT-PCR
Total RNA from liver tissue was isolated using the peq-GOLD RNAPureTM Kit (Peqlab, Erlangen, Germany). Reverse-transcription was performed as previously described [23] . Relative quantitative gene expression was measured via RT-PCR using a 7300 Real Time PCR System with SDS software 1.3.1 (Applied Biosystems, Foster City, CA) and a SYBR Green PCR Kit (Invitrogen, Carlsbad, CA). GAPDH expression was used as internal standard. The primer sequences are given in Supplementary Table 1 .
Immunofluorescence staining
Immunofluorescence staining was performed on frozen liver sections. Hepatocyte proliferation was quantified by counting the number of nuclei positive for either Ki67 or pH3 relative to the total nuclei per power field (200×) stained with 4′, 6-diamidino-2-phenylindole (DAPI). Stained microscopic images were acquired with a Zeiss Axio Imager.Z1 microscope, AxioCam MRm camera using Axiovision 4.8 software (all from Carl Zeiss, Inc., Oberkochen, Germany).
In vitro kinase assay
Immunoprecipitations and kinase assays were performed as described previously [11] with minor modifications. Briefly, 500 μg of liver protein extract was incubated with antibodies against CDK2 (sc-6248, Santa Cruz) or CDK1 (sc-54; Santa Cruz Biotechnology) overnight at 4°C in Nonidet P-40 lysis buffer containing protease inhibitors (cOmpleteTM Mini, Roche, Mannheim, Germany). Antibody/ protein complexes were coupled to protein A/G agarose beads (Santa Cruz) for 1 h at 4°C and subsequently washed three times in NP40-lysis buffer and in kinase buffer (50 mM HEPES pH7.5; 10 mM MgCl 2 ; 10 mM β-Glycerophosphate, 1 mM DTT), respectively. Kinase assays were performed by incubating the immunoprecipitated protein complexes in kinase buffer containing 15 μM ATP, 160 Bq [γ-32P] ATP (Hartmann, Braunschweig, Germany), and 2 μg of recombinant histone H1 (Roche) in a total volume of 30 µl for 30 min at 4°C. The reaction was inactivated with SDS/PAGE sample buffer and resolved by electrophoresis on polyacrylamide gels. Immobilized gels were exposed to autoradiography (Hyperfilm, GE Healtcare, Freiburg, Germany).
Statistical analysis
Data are presented as mean ± standard deviation of the mean. Statistical significance was determined by a twotailed Students t test. For each experiment, control mice were compared to each other and NEMO-deficient mice were compared among each other.
